# SVRA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SVRA) · [Earnings tab](https://www.lopjlb.com/stock/SVRA?tab=earnings)

Updated: 2026-11-11T07:40:07

Quarters analyzed: 8

## Cross-quarter narrative

Across the eleven earnings calls from late 2018 through mid‑2020, Savara’s story shifted from early enrollment milestones and modest cash to a more complex picture of mixed clinical outcomes, regulatory engagement, and a strengthening balance sheet tempered by COVID‑19 disruptions. Early calls highlighted completion of enrollment for the IMPALA aPAP study and a target for top‑line data in Q2 2019, alongside a modest cash runway. By Q2 2019 the primary endpoint of IMPALA was missed, prompting FDA feedback and a narrative of insufficient data in Q3 2019, yet the company secured Breakthrough Therapy Designation and reported encouraging open‑label results later that year. AeroVanc enrollment consistently lagged, moving from at‑risk status to delayed timelines and a projected early‑2021 read‑out. Cash balances rose sharply from roughly $12 M to over $120 M after a $75 M financing, extending runway into 2022. In 2020 the pipeline broadened with a bronchiectasis program and the Apulmiq candidate, while COVID‑19 forced a pause in CF enrollment and pressured AVAIL enrollment. Management tone remained muted, reflecting uncertainty despite the cash uplift and new regulatory milestones.

## Latest CallCard · Q2

Savara finalized IMPALA 2 Phase III design (160 patients, Q1 2021 start), AVAIL top-line expected early 2021 despite COVID enrollment shortfall, $100M cash with $25M debt, transitioning to event-driven webcasts.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management expressed enthusiasm for aPAP progr

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2020 Q2:** Savara finalized IMPALA 2 Phase III design (160 patients, Q1 2021 start), AVAIL top-line expected early 2021 despite COVID enrollment shortfall, $100M cash with $25M debt, transitioning to event-driven webcasts.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management expressed enthusiasm for aPAP progr
- **2020 Q1:** Savara advances IMPALA 2 design for aPAP, adds Apulmiq for NCFB, pauses CF enrollment due to COVID-19, cash runway into 2022.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights strong start, collaborative FDA discussions, pipeline expansion, and cash strength, but acknowledges COVID-19 
- **2019 Q4:** Savara ends 2019 with $122M cash after $75M financing, Breakthrough Therapy Designation for Molgradex in aPAP, positive IMPALA open-label data, focusing on IMPALA 2 Phase 3; AVAIL enrollment near completion but coronavirus may limit to ~140 patients; NTM program under review after mixed OPTIMA resul
- **2019 Q3:** Savara Q3 2019: FDA says IMPALA data insufficient for Molgradex approval; company pursuing regulatory dialogue with FDA and EMA, believes totality of data shows efficacy; AeroVanc enrollment 123/150, targeting H1 2020 completion; cash $106M funds ops into 2021.','tone': {'mgmt': 0.1, 'mgmt_rationale
- **2019 Q2:** Savara Q2 2019: IMPALA Phase 3 missed primary endpoint but secondary endpoints support Molgradex efficacy; FDA Type C meeting in October; AeroVanc enrollment delayed to H1 2020; cash $112M funds ops into 2021.','tone': {'mgmt': 0.2, 'mgmt_rationale': 'Management acknowledges IMPALA primary endpoint 
- **2019 Q1:** Savara nears IMPALA Phase 3 top-line readout for Molgradex in aPAP (June 2019), with BLA planned H1 2020; AeroVanc enrollment challenging but reaffirmed; new bronchiectasis program advancing. Cash $105M funds operations into late 2020. Fast Track granted. Commercial prep underway. Bronchiectasis Pha
- **2018 Q4:** Savara reports 2018 results, highlights IMPALA Phase 3 readout in Q2 2019 for
- **2018 Q3:** Savara completed enrollment in IMPALA (aPAP) and OPTIMA (NTM) studies, targeting top-line data Q2 2019; AeroVanc enrollment at 126/200 with risk of delay; cash ~$12M plus $45.8M offering provides runway into late 2020.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'Management highlights substantial progr

## Theme arcs

- **Molgradex clinical outcomes** (deteriorating): Missed primary endpoint and FDA concerns after initial optimism
- **AeroVanc enrollment** (deteriorating): Repeated enrollment shortfalls and delayed read‑out
- **Cash position** (improving): Cash grew from $12 M to >$120 M, extending runway
- **Regulatory engagement** (new): Breakthrough Therapy Designation and multiple FDA/EMA dialogues
- **COVID‑19 impact** (new): Paused CF enrollment and limited AVAIL patient accrual
- **Pipeline expansion** (new): Bronchiectasis program and Apulmiq for NCFB added

## Guidance path

2018 Q3:vague → 2018 Q4:vague → 2019 Q1:maintained → 2019 Q2:vague → 2019 Q3:vague → 2019 Q4:vague → 2020 Q1:vague → 2020 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SVRA`